April 23, 2018 / 12:52 PM / a month ago

BRIEF-Azurrx Biopharma And Mayoly-Spindler Announce Additional Positive Interim Data For MS1819-SD Phase II

April 23 (Reuters) - AzurRx BioPharma Inc:

* AZURRX BIOPHARMA AND MAYOLY-SPINDLER ANNOUNCE ADDITIONAL POSITIVE INTERIM DATA FOR MS1819-SD PHASE II IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI)

* AZURRX BIOPHARMA INC - OBSERVED BOTH CLINICAL ACTIVITY AND A CLEAR DOSE RESPONSE IN ITS ONGOING PHASE IIA TRIAL OF MS1819-SD

* AZURRX BIOPHARMA INC - HIGHEST MS1819-SD DOSE COHORT CONTINUED TO SHOW GREATER THAN 21% IMPROVEMENT IN CFA IN EVALUABLE PATIENTS

* AZURRX BIOPHARMA INC - MAXIMAL ABSOLUTE CFA RESPONSE TO TREATMENT WAS UP TO 57%, WITH AN INVERSE RELATIONSHIP TO BASELINE CFA

* AZURRX BIOPHARMA INC - NO SERIOUS ADVERSE EVENTS OR NOTABLE MILD TO MODERATE EVENTS HAVE BEEN REPORTED IN PHASE IIA TRIAL Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below